Abstract

The aim was to investigate the effect of clinico-radiologic variables, including total tumor (Ttotal) size and clinical T category, on the prognosis of patients with stage IA (T1N0M0) lung adenocarcinomas appearing as part-solid nodules (PSNs). This institutional review board-approved retrospective study included 506 patients (male:female = 200:306; median age, 62 years) with PSNs of the adenocarcinoma spectrum in clinical stage IA who underwent standard lobectomy at a single tertiary medical center. Prognostic stratification of the patients in terms of disease-free survival was analyzed with variables including age, sex, Ttotal size, solid portion size, clinical T category, and tumor location using univariate and subsequent multivariate Cox regression analysis. Subgroup analysis was performed to reveal the effect of the Ttotal size at each clinical T category. Multivariate Cox regression analysis demonstrated that Ttotal size*cT1b [interaction term; hazard ratio (HR) = 1.091; 95% confidence interval (CI): 1.015, 1.173; p = 0.019] and cT1c (HR = 68.436; 95% CI: 2.797, 1674.415; p = 0.010) were independent risk factors for the tumor recurrence. When patients with cT1b were dichotomized based on a Ttotal size cutoff of 3.0 cm, PSNs with Ttotal > 3.0 cm showed a significantly worse outcome (HR = 3.796; 95% CI: 1.006, 14.317; p = 0.049). No significant difference was observed in the probability of recurrence between cT1b with Ttotal > 3.0 cm and cT1c (p = 0.915). Ttotal size is a significant prognostic factor in adenocarcinoma patients in cT1b without lymph node or distant metastasis. PSNs in cT1b with Ttotal > 3.0 cm have a comparable risk of lung cancer recurrence to those in cT1c. • Current T descriptor was a powerful prognostic factor in stage IA adenocarcinomas appearing as part-solid nodules. • Total tumor size further stratified risk of recurrence of adenocarcinomas in cT1b. • Upstaging of tumors in cT1b with total tumor size > 3.0 cm may be more appropriate.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call